nogapendekin alfa inbakicept-pmln
Drug Details
- Generic Name
- nogapendekin alfa inbakicept-pmln
- Brand Names
- ANKTIVA
- Application Number
- BLA761336
- Sponsor
- Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
- NDC Codes
- 1
- Dosage Forms
- SOLUTION
- Routes
- INTRAVESICAL
- Active Ingredients
- NOGAPENDEKIN ALFA INBAKICEPT-PMLN
Indications and Usage
1 INDICATIONS AND USAGE ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ( 1 )